Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of MXN 28.87 billion. The enterprise value is 20.76 billion.

Market Cap	28.87B
Enterprise Value	20.76B

Important Dates

The last earnings date was Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	162.94M
Shares Outstanding	n/a
Shares Change (YoY)	+13.74%
Shares Change (QoQ)	+1.74%
Owned by Insiders (%)	0.58%
Owned by Institutions (%)	59.22%
Float	140.55M

Valuation Ratios

The trailing PE ratio is 3.64.

PE Ratio	3.64
Forward PE	n/a
PS Ratio	1.43
PB Ratio	-12.55
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.95, with an EV/FCF ratio of -4.61.

EV / Earnings	2.62
EV / Sales	1.04
EV / EBITDA	1.95
EV / EBIT	2.08
EV / FCF	-4.61

Financial Position

The company has a current ratio of 2.13

Current Ratio	2.13
Quick Ratio	1.83
Debt / Equity	n/a
Debt / EBITDA	0.46
Debt / FCF	-1.11
Interest Coverage	24.98

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	25.72%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	78.60%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	27.00M
Profits Per Employee	10.58M
Employee Count	749
Asset Turnover	0.82
Inventory Turnover	39.01

Taxes

In the past 12 months, Novavax has paid 33.58 million in taxes.

Income Tax	33.58M
Effective Tax Rate	0.42%

Stock Price Statistics

The stock price has increased by +9.38% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+9.38%
50-Day Moving Average	143.94
200-Day Moving Average	140.87
Relative Strength Index (RSI)	57.38
Average Volume (20 Days)	1,051

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.31

Income Statement

In the last 12 months, Novavax had revenue of MXN 20.23 billion and earned 7.93 billion in profits. Earnings per share was 46.36.

Revenue	20.23B
Gross Profit	13.10B
Operating Income	10.14B
Pretax Income	7.96B
Net Income	7.93B
EBITDA	10.64B
EBIT	10.14B
Earnings Per Share (EPS)	46.36

Full Income Statement

Balance Sheet

The company has 13.23 billion in cash and 5.01 billion in debt, giving a net cash position of 8.23 billion.

Cash & Cash Equivalents	13.23B
Total Debt	5.01B
Net Cash	8.23B
Net Cash Per Share	n/a
Equity (Book Value)	-2.30B
Book Value Per Share	-14.15
Working Capital	9.33B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.40 billion and capital expenditures -100.10 million, giving a free cash flow of -4.50 billion.

Operating Cash Flow	-4.40B
Capital Expenditures	-100.10M
Free Cash Flow	-4.50B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 64.77%, with operating and profit margins of 50.13% and 39.19%.

Gross Margin	64.77%
Operating Margin	50.13%
Pretax Margin	39.36%
Profit Margin	39.19%
EBITDA Margin	52.59%
EBIT Margin	50.13%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.74%
Shareholder Yield	-13.74%
Earnings Yield	27.46%
FCF Yield	-15.60%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novavax has an Altman Z-Score of -1.81 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.81
Piotroski F-Score	5